不同年龄,不同表型:来自三级中心的幼年与成人起病皮肌炎比较分析
该回顾性队列纳入180例符合2017 EULAR/ACR分类标准的皮肌炎患者(JDM 86例,AoDM 94例),比较两组临床特征、血清学、治疗与结局。JDM以钙质沉着和关节炎更常见,无激素缓解率更高;AoDM恶性肿瘤相关例仅见于成人组,且诊断年龄与死亡和恶性肿瘤独立相关。
要点
- JDM钙质沉着(33%)和关节炎显著多于AoDM(P=0.007和P=0.049)。
- JDM无激素缓解率40.3% vs AoDM 89.6%(P=0.020),无药物缓解率40.3% vs 16.7%(P=0.020)。
- 恶性肿瘤相关皮肌炎仅见于AoDM(n=25,26.6%),诊断年龄与死亡和恶性肿瘤独立相关。
核心结论
- JDM与AoDM并非仅年龄定义的变异,而是具有不同临床、血清学和预后特征。
- JDM以钙质沉着和较好缓解及生存为特点,AoDM与恶性肿瘤和更高死亡负担强烈相关。
研究设计与样本
- 回顾性队列纳入180例符合2017 EULAR/ACR分类标准的皮肌炎患者,1995至2025年在同一三级中心儿科和成人风湿科随访。
- 诊断年龄小于16岁归为JDM;共86例JDM和94例AoDM。
主要发现
- 年龄呈双峰分布,峰值在6.8岁和45.7岁;女性占67.8%,中位随访5.9年。
- 肌肉无力(86.7%)和皮肤受累(98.3%)最常见;钙质沉着在JDM频繁(33%),成人罕见(1例)。
- JDM领先自身抗体为抗NXP2(31.4%,11/35),AoDM为抗合成酶抗体(34.6%,9/26)。
- 恶性肿瘤相关皮肌炎仅见于AoDM(n=25,26.6%);诊断年龄与死亡(OR 1.07/年,95%CI 1.02-1.11)和恶性肿瘤(OR 1.05/年,95%CI 1.00-1.10)独立相关。
关键数值与推荐
- JDM无激素缓解率40.3% vs AoDM 89.6%(P=0.020);无药物缓解率40.3% vs 16.7%(P=0.020)。
- 钙质沉着与JDM显著相关(P=0.007),关节炎与JDM显著相关(P=0.049)。
临床怎么用
- 对JDM应关注钙质沉着和关节炎评估,对AoDM应重视恶性肿瘤筛查和死亡风险管理。
- 年龄可作为皮肌炎表型分层和个体化诊疗策略的依据。
局限性
- 单中心回顾性队列设计可能限制外推性。
- 自身抗体数据仅部分患者可获取(JDM 35例,AoDM 26例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate age-related differences in clinical features, serological profiles, diagnostic approaches, treatment strategies and outcomes among juvenile- and adult-onset dermatomyositis (JDM and AoDM) patients managed at the same tertiary referral centre. METHODS: This retrospective cohort included 180 patients with dermatomyositis meeting the 2017 EULAR/ACR classification criteria and followed between 1995 and 2025 at the paediatric and adult rheumatology clinics. Diagnosis before 16 years was classified as JDM. RESULTS: Among 180 patients, 86 had JDM and 94 had AoDM. A bimodal age distribution was observed, with peaks at 6.8 and 45.7 years. 67.8% were female; median follow-up was 5.9 years. Muscle weakness (86.7%) and cutaneous involvement (98.3%) were most common findings. Calcinosis was frequent in JDM (33%) but rare in adults (one case). Both calcinosis and arthritis were significantly associated with JDM (P = 0.007 and P = 0.049). Anti-NXP2 was the leading JDM autoantibody (31.4%, 11/35), whereas anti-synthetase antibodies (34.6%, 9/26) in AoDM. Glucocorticoids were given to both groups; however, steroid-free (40.3% vs 89.6%, P = 0.020) and drug-free remission rates (40.3% vs 16.7%, P = 0.020) were higher in JDM. Malignancy-associated dermatomyositis occurred only in AoDM (n = 25, 26.6%). Age at diagnosis was independently associated with both mortality (OR 1.07 per year, 95% CI: 1.02-1.11) and malignancy (OR 1.05 per year, 95% CI: 1.00-1.10). CONCLUSION: JDM and AoDM are not merely age-defined variants but display distinct clinical, serological and prognostic profiles. JDM shows calcinosis and better remission and survival, whereas AoDM is strongly associated with malignancy and higher mortality burden, highlighting the need for age‑tailored diagnostic and management strategies.
引用
- Aslan E, Karakoc A, Ozturk P, et al. Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary centre. Rheumatology (Oxford). 2026. PMID: 42623129. doi:10.1093/rheumatology/keag455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。